Myriad Genetics Q1 revenue $181.2M (+10% YoY); raises FY23 revenue guidance midpoint

MYRIAD GENETICS INC

2023-Q1 EPS reported -$0.67 revenue$181,200,000

Q1 GAAP EPS $(0.67); adjusted EPS $(0.21); revenue $181.2M (+10% YoY).
Testing volumes +21% ex-SneakPeek; hereditary cancer +24%, GeneSight +31% YoY.
FY23 revenue guidance raised to $730-750M (previous $720-750M); gross margin 68-70% reaffirmed.
GAAP gross margin 67.3% (down 360bps YoY) due to product mix and $12.4M prior-year benefit.
Ended Q1 with $109.1M cash, no debt; management targets profitability by Q4 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MYRIAD GENETICS INC reported the three months ended March 31, 2023 results: EPS $(0.67). Guidance raised.

Period: the three months ended March 31, 2023
EPS: $(0.67)
Guidance: raised
Result: reported results

Exact text from the filing

Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

MYRIAD GENETICS INC filing history →

Source: SEC EDGAR

accession 0000899923-23-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.